Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jamie Freeman
Leicester boss gives honest injury update ahead of Palace trip, including Vardy and Daka
Microsoft Cares About Your Privacy Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
Down Syndrome Awareness Month: What Support Really Looks Like
It takes work to be friends with my family. The life of a parent of a child with a disability is hard, that’s not a secret. People tend to think they understand the hard parts: sleepless nights, endless doctor’s appointments, advocating for their educational rights, and on and on . . . You want to know what the hardest part is? INCLUSION. You WANT your kid to have friends. You WANT your child included in the neighborhood games.
Wearable temperature device warns for cancer complications, study finds
13 August 2021 Posted in Cancer Research, News | Tagged Cancer Research, Drug development, immuno-oncology, Oncology, Research Researchers from the University of Michigan Rogel Cancer Center found that a wearable temperature sensor was able to detect dangerous complications in hospitalised cancer patients hours earlier than routine monitoring.
Bioelectronic assays: Setting a standard for immunotherapy potency measurement
Bioelectronic assays allow scientists to precisely and continuously monitor cultured cells without labels or dyes. Dr Jim Ross, Chief Technology Officer and co-founder of Axion Biosystems, elaborates. Young industry, massive momentum Although cell-based immunotherapies for cancer treatment are relatively new, they are poised to take the biomedical world by storm.
First patient dosed with Gadeta’s gamma delta TCR cell therapy
14 July 2021 Posted in Cancer Research, News, USA News | Tagged Cancer Research, Clinical trials, Drug development, Drug discovery, Tumour biology Gadeta, a clinical-stage company developing gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, has announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer.
Biotech’s pursuit of next-generation CAR-T
Pierre-Louis Joffrin leads Corporate Development at Mogrify. He examines immunotherapies including an assessment of the next generation of stem cell derived products. Biotech has joined the pursuit of next-generation CAR-Ts and it’s not subtle. Some new, others having pivoted towards the area, there are now over 100 companies working on CAR-Ts or derivatives around the world.
Innovation driving cell therapies toward the clinic
Sean Chang, Product Manager, Cell and Gene Therapy at Thermo Fisher Scientific It has been four years since the first Chimeric Antigen Receptor T-cell (CAR T) therapy drug, Kymriah1, was approved by the US Food and Drug Administration (FDA) for the treatment of B-cell acute lymphoblastic leukaemia (ALL).
Immune checkpoint inhibitors: What are the risks?
Immuno-oncology has advanced greatly through T cell-based therapeutic approaches (particularly immune checkpoint inhibitors). However, immune checkpoint inhibitors (ICIs) aren’t efficacious in all patients, and they carry risks. What are these risks? Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences speaks to Lu Rahman. Preclinical in vivo models serve as important tools for studying the mechanisms of tumor biology and immuno-oncology (I/O).
Takara Bio agreement with BioNTech Cell & Gene Therapies
25 June 2021 Posted in News | Tagged CAR-T, Cell and gene therapy Takara Bio has entered into a License and Supply Agreement with BioNTech Cell & Gene Therapies. Takara Bio will grant BioNTech a commercial license to use applicable patents relating to RetroNectin, and will provide BioNTech with supplies of RetroNectin.
Aleta and Cancer Research UK collaborate to advance blood cancer therapy
24 June 2021 Posted in News | Tagged Biotherapeutics, Cancer Research, CAR-T, Cell therapy, Clinical trials, Drug development Aleta Biotherapeutics and Cancer Research UK have collaborated to advance the early phase clinical development of Aleta’s CAR-T cell engager candidate, ALETA-001.
New insight into when CAR T is effective against childhood leukaemia
25 May 2021 Posted in Cancer Research, News | Tagged Cancer Research, Drug development, T-Cells Scientists and clinicians at UCL and Great Ormond Street Hospital (GOSH) studying the effectiveness of CAR T-cell therapies in children with leukaemia, have discovered a small sub-set of T-cells that are likely to play a key role in whether the treatment is successful.
What FDA Clearance means for GammaDelta cell cancer therapy
21 May 2021 Posted in News | Tagged Biotherapeutics, Cell therapy, FDA, Tumour biology GammaDelta Therapeutics’ Investigational New Drug (IND) application has been cleared by the US Food and Drug Administration (FDA) for its allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies.
Gilead Company, Kite, to share scientific advances in virtual meeting
9 March 2021 Posted in News | Tagged Biopharmaceutical, Blood transplant, events, Marrow transplant Biopharmaceutical company Kite will share its latest scientific advances in cell therapy research at the 47th Virtual Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 14-17, 2021. 11 abstracts will be presented which demonstrate Kite’s commitment to innovation in cell therapy for patients with blood cancers.
Horizon’s iPSC cell line engineering services
Horizon’s iPSC cell line engineering services 2 February 2021 , Brought to you by Horizon View Horizon can help researchers work with the biologically relevant cell models (immune cells, induced pluripotent derived cardiac and neural cells, and organoids) that closely mimic the end-stage biology of interest. With over a decade of CRISPR/Cas cell line engineering experience, Horizon’s iPSC editing platform is designed to enable efficient and precise genomic modifications in a […]
Combined approach could boost breast cancer immunotherapy, study suggests
4 January 2021 Posted in Cancer Research, News | Tagged Drug discovery, Oncology Activating an immune signalling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers at the University of North Carolina.
CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma
8 December 2020 Posted in Cancer Research, News, Videos | Tagged CAR-T, Oncology, Therapeutics A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Collaboration aims to develop targeted, effective cancer immunotherapies
Immunai has joined forces with Baylor College of Medicine to bring more targeted and effective cancer therapies to market. Leveraging Immunai’s single-cell technology and artificial intelligence, Baylor and Immunai will analyse natural killer T (NKT) cells and genetically engineer them into immunotherapies that target a variety of cancers, including solid tumours.
Will the next generation of CAR-T cells be modified using base editing?
By Dr Jamie Freeman Volume 21 Issue 3 - Summer 2020 Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies.
Webinar " Make Your Virtual Trainings Events to Remember
When saved and published, this page is accessible in this URL: https://www.trainingmagnetwork.com/ URL Code Only alphanumeric characters and hyphen are allowed. You may use ~DETAILS_CALC~ variable in Content and it will convert automatically. Page URL Enter the exact URL where you want this Guide Page to appear, or use "/" to display in homepage. Reminder Message Enter the content of the Reminder Email. Reminder URL Enter the URL which will be embeded in the Reminder Email.
2020 UK Americana Awards nominees announced
The nominees for the 2020 UK Americana Awards have been revealed. After four sell-out years in Hackney Empire, the ceremony will move to the bigger venue of Troxy in Limehouse, taking place on Thursday January 30, 2020. Yola is nominated for two awards, with her debut solo album Walk Through Fire nominated in the UK Album of the Year category while she is also up for UK Artist of the Year. Walk Through Fire reached Number 1 on the UK's Official Americana Albums Chart in March 2019.
eBook: Expression Systems — Increasing Productivity and Reducing Costs - BioProcess International
Biopharmaceutical manufacturers are facing increasing pressures to improve productivity and reduce time to clinic and market. Increasing productivity begins with selecting the appropriate expression system for each protein. Current efforts to boost expression titers also are focused on implementing selection/screening technologies, engineering Chinese hamster ovary (CHO) expression systems, and accelerating timelines for the development of complex next-generation therapies.
Improving CHO Cells for Biomanufacturing: Using GS-KO CHO SOURCE - BioProcess International
Chinese hamster ovary (CHO) cells have been used in biomanufacturing for decades because of their robust capacity to express a range of proteins, such as therapeutic enzymes and monoclonal antibodies (MAbs) at titers measured in multiple grams per liter of culture. Within the available suite of CHO cell lines, the glutamine synthetase knockout (GS-KO) selection system provides industry-leading speed to the identification of high-producing clones for use in biomanufacturing.
Horizon’s Alternative CHO K1 GS Knockout Cell Line Drives Access to Cutting-Edge Biomanufacturing Cell Lines - BioProcess International
Chinese hamster ovary (CHO) cells are the expression system of choice for the manufacturing of biotherapeutics. They have the capacity to express a range of proteins such as therapeutic enzymes or monoclonal antibodies at multiple gram per liter titers. As expression technologies have developed, obtaining such titers has been achieved mainly through improvements to media and feed.
Ask the Expert: Developing a Whole-Genome CRISPR Screen to Improve Chinese Hamster Ovary Cells for Biomanufacturing - BioProcess International
Great strides have been made in increasing the yield of biotherapeutic proteins mainly through process improvements with a focus on media and feed strategies. But aside from single-gene knockouts to allow for metabolic selection systems, the Chinese hamster ovary (CHO) host cell line remains largely unchanged from what was used 30 years ago.
Get in on the act
WHAT IS IT? ACT-PR is very simple. So simple it takes just 60 seconds to get started. Try it for yourself on the website – push the ‘start learning’ button. However, just because it’s easy to learn doesn’t mean it’s lightweight or not backed up by research. ACT-PR is based on Acceptance and Commitment Therapy (ACT), which has an evidence base on a par with CBT. The peer model is based on the ACT Matrix, which is a simpler training format.
Engineering Biotherapeutic Quality
The first recombinant protein licensed for use by the U.S. FDA was human insulin in 1982. This was closely followed by tissue plasminogen activator (tPA), the first complex glycosylated protein generated in mammalian cells to be licensed for therapeutic use in 1987.
When My Doctor Said the Most Powerful Thing After My Son's Down Syndrome Diagnosis
With my son Benny turning 2 years old next month (eek), I’m doing a lot of reflecting. I’ve made so many friends, all of whom are on this beautiful journey with me and have little ones with a little extra. Inevitably, when you first get to talking with someone who also has a child with Down syndrome, the question, “How did you find out?” always comes up. I’ve heard the most upsetting horror stories that make me sick to my stomach.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jamie
Contact Jamie, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack